tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

RAIN

Rain Therapeutics Revamps Governance Post-Merger
Market NewsRain Therapeutics Revamps Governance Post-Merger
6M ago
8K
RAIN
Rain Therapeutics Updates Security Holder Rights
PremiumMarket News
Rain Therapeutics Updates Security Holder Rights
6M ago
8K
RAIN
Rain Therapeutics Announces Merger and Nasdaq Delisting
PremiumMarket News
Rain Therapeutics Announces Merger and Nasdaq Delisting
6M ago
8K
RAIN
Rain Therapeutics Merges with Pathos AI Subsidiary
PremiumMarket News
Rain Therapeutics Merges with Pathos AI Subsidiary
6M ago
8K
RAIN
Rain Therapeutics Enters Merger with Pathos AI Despite Legal Hurdles
PremiumMarket News
Rain Therapeutics Enters Merger with Pathos AI Despite Legal Hurdles
6M ago
8K
RAIN
Rain Therapeutics trading resumes
PremiumThe FlyRain Therapeutics trading resumes
7M ago
RAIN
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
PremiumPress Releases
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
7M ago
RAIN
Rain Oncology to be Acquired by Pathos AI for $1.16 in cash per share
PremiumThe Fly
Rain Oncology to be Acquired by Pathos AI for $1.16 in cash per share
7M ago
RAIN
Rain Therapeutics trading halted, news pending
PremiumThe Fly
Rain Therapeutics trading halted, news pending
7M ago
RAIN
Rain Oncology reports Q3 EPS (19c), consensus (27c)
PremiumThe Fly
Rain Oncology reports Q3 EPS (19c), consensus (27c)
9M ago
RAIN
Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
PremiumPress Releases
Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
9M ago
RAIN
Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
PremiumPress Releases
Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
9M ago
RAIN
Rain Oncology confirms receipt of unsolicited proposal from Concentra
PremiumThe FlyRain Oncology confirms receipt of unsolicited proposal from Concentra
9M ago
RAIN
Rain Oncology price target lowered to $1 from $1.50 at Citi
PremiumThe Fly
Rain Oncology price target lowered to $1 from $1.50 at Citi
10M ago
RAIN
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
PremiumPress Releases
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
12M ago
RAIN
Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs
PremiumPress Releases
Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs
1y ago
RAIN
Rain Oncology Plummets after Lead Candidate Disappoints in Phase 3
PremiumMarket News
Rain Oncology Plummets after Lead Candidate Disappoints in Phase 3
1y ago
RAIN
Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma
PremiumPress Releases
Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma
1y ago
RAIN
Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress
PremiumPress Releases
Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress
1y ago
RAIN
Roth MKM biotech analysts to hold analyst/industry conference call
PremiumThe FlyRoth MKM biotech analysts to hold analyst/industry conference call
1y ago
APGN
RAIN
Roth MKM biotech analysts to hold analyst/industry conference call
PremiumThe Fly
Roth MKM biotech analysts to hold analyst/industry conference call
1y ago
APGN
RAIN
Roth MKM biotech analysts to hold analyst/industry conference call
PremiumThe Fly
Roth MKM biotech analysts to hold analyst/industry conference call
1y ago
APGN
RAIN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >